SUFU 2011 - Sanctura XR muscarinic anatagonist resist transport (SMART) across the blood-brain barrier (BBB): A prospective neurocognitive biodistribution and pharmacokinetic study of extended release trospium

PHOENIX, AZ USA (UroToday.com) - Antimuscarinic mediations have the potential to cause clinically relevant impairment of CNS function, and preclinical data strongly support different propensities of OAB drugs to cross the BBB (tertiary/quaternary amine). This open-label, non-comparator study was to determine if Sanctura crosses the BBB and if it results in a clinically significant memory effect.

Cerebrospinal fluid (CSF) was tested in human volunteers (n=12, 65-75 yrs of age). The Hopkins Verbal Learning Test-Revised was used to test memory. CSF in these subjects did not detect any trospium at peak plasma levels and there was no change in memory on the Hopkins test.

Their conclusion was that trospium is safe in elderly in relation to cognition.

Presented by Michael Oefelein, Gary Kay, Howard Goldman. John Ling, Kavitha Bhasi, Cara Tannenbaum, and David Statskin at the Society for Urodynamics and Female Urology (SUFU) 2011 Winter Meeting - March 1 - 5, 2011 - Arizona Biltmore, Phoenix, Arizona, USA

Reported for UroToday by Diane K. Newman, RNC, MSN, CRNP, FAAN and Continence Nurse Practitioner Specialist - University of Pennsylvania Medical Center.

The opinions expressed in this article are those of the UroToday.com Contributing Medical Editor and do not necessarily reflect the viewpoints of the Society for Urodynamics and Female Urology.

View Full SUFU 2011 Meeting Coverage

Login